Document is current
Any future updates will be listed below
-
Authors
Coelho, Matthew A. https://orcid.org/0000-0003-3737-2468
Strauss, Magdalena E. https://orcid.org/0000-0002-6089-8049
Watterson, Alex
Cooper, Sarah
Bhosle, Shriram https://orcid.org/0000-0002-7638-2899
Illuzzi, Giuditta
Karakoc, Emre
Dinçer, Cansu
Vieira, Sara F. https://orcid.org/0000-0002-1021-3021
Sharma, Mamta
Moullet, Marie
Conticelli, Daniela https://orcid.org/0000-0003-4661-9776
Koeppel, Jonas https://orcid.org/0000-0003-1306-3994
McCarten, Katrina
Cattaneo, Chiara M. https://orcid.org/0000-0002-8168-8649
Veninga, Vivien
Picco, Gabriele
Parts, Leopold
Forment, Josep V.
Voest, Emile E. https://orcid.org/0000-0001-8249-9586
Marioni, John C. https://orcid.org/0000-0001-9092-0852
Bassett, Andrew https://orcid.org/0000-0003-1632-9137
Garnett, Mathew J. https://orcid.org/0000-0002-2618-4237
-
Funding
Funding for this research was provided by:
Wellcome Trust (206194, 220442/Z/20/Z)
- License Information
-
More Information
Article History
Received: 1 December 2023
Accepted: 13 September 2024
First Online: 18 October 2024
Competing interests
: M.J.G. has received research grants from AstraZeneca, GSK and Astex Pharmaceuticals, and is a founder and advisor for Mosaic Therapeutics. J.C.M. has been an employee of Genentech since September 2022. A.B. is a founder and consultant for EnsoCell Therapeutics. M.A.C. and M.J.G. are inventors on patent applications that encompass work described in this paper. J.V.F. and G.I. are employees and shareholders of AstraZeneca. E.E.V. is a founder and advisor for Mosaic Therapeutics. The other authors declare no competing interests.
